Congress, held from June 12 to June 15 in Milan, Italy, updated results from the Phase II registrational iMMagine-1 study ...

A compelling session at the EHA Congress explored how space research is reshaping our understanding of hematologic processes.

Congress, hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible worldwide.

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best stocks to buy for beginners now. On June 12, Bristol Myers Squibb ...

Sessions and posters at the 2025 European Hematology Association Congress evaluated the potential and real-world practices of using artificial intelligence (AI) to predict and improve outcomes for ...

Silence Therapeutics presents additional data from phase 1 study of divesiran as potential first-in-class siRNA treatment for polycythemia vera: London Monday, June 16, 2025, 18:0 ...

Analysts at Truist Securities called J&J’s CAR-T readout “compelling,” noting that the efficacy figures could position the ...

Incyte's INCA033989 showed early efficacy and strong tolerability in essential thrombocythemia patients with mutCALR, ...

The FDA granted fast track designation to nuvisertib for those with intermediate or high-risk myelofibrosis, which ...

Australian researchers have demonstrated that the use of a new, less toxic drug combination after stem cell transplants for leukaemia significantly improves patient outcomes post-transplant, reducing ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the best stocks to buy for beginners now. On June 12, Bristol Myers Squibb ...

While the renal benefits of oral semaglutide vs placebo in the SOUL trial didn't match the effects seen with the injectable ...